Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Microarray analysis of DNA damage repair gene expression profiles in cervical cancer cells radioresistant to 252Cf neutron and X-rays

Authors: Yi Qing, Xue-Qin Yang, Zhao-Yang Zhong, Xin Lei, Jia-Yin Xie, Meng-Xia Li, De-Bing Xiang, Zeng-Peng Li, Zhen-Zhou Yang, Ge Wang, Dong Wang

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

The aim of the study was to obtain stable radioresistant sub-lines from the human cervical cancer cell line HeLa by prolonged exposure to 252Cf neutron and X-rays. Radioresistance mechanisms were investigated in the resulting cells using microarray analysis of DNA damage repair genes.

Methods

HeLa cells were treated with fractionated 252Cf neutron and X-rays, with a cumulative dose of 75 Gy each, over 8 months, yielding the sub-lines HeLaNR and HeLaXR. Radioresistant characteristics were detected by clone formation assay, ultrastructural observations, cell doubling time, cell cycle distribution, and apoptosis assay. Gene expression patterns of the radioresistant sub-lines were studied through microarray analysis and verified by Western blotting and real-time PCR.

Results

The radioresistant sub-lines HeLaNR and HeLaXR were more radioresisitant to 252Cf neutron and X-rays than parental HeLa cells by detecting their radioresistant characteristics, respectively. Compared to HeLa cells, the expression of 24 genes was significantly altered by at least 2-fold in HeLaNR cells. Of these, 19 genes were up-regulated and 5 down-regulated. In HeLaXR cells, 41 genes were significantly altered by at least 2-fold; 38 genes were up-regulated and 3 down-regulated.

Conclusions

Chronic exposure of cells to ionizing radiation induces adaptive responses that enhance tolerance of ionizing radiation and allow investigations of cellular radioresistance mechanisms. The insights gained into the molecular mechanisms activated by these "radioresistance" genes will lead to new therapeutic targets for cervical cancer.
Appendix
Available only for authorised users
Literature
1.
Pontén J, Adami HO, Bergström R, Dillner J, Friberg LG, Gustafsson L, Miller AB, Parkin DM, Sparén P, Trichopoulos D: Strategies for global control of cervical cancer. Int J Cancer. 1995, 60: 1-26. 10.1002/ijc.2910600102.CrossRefPubMed
2.
Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, Nakamura Y, Katagiri T: Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004, 60: 237-248.CrossRefPubMed
3.
Ma BB, Bristow RG, Kim J, Siu LL: Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol. 2003, 21: 2760-2776. 10.1200/JCO.2003.10.044.CrossRefPubMed
4.
5.
Marjina LA, Kiseleva MV, Chekhonadsky VN: Radiation treatment of the cervix uteri cancer with usage of high activity 252Cf sources. Radiother Oncol. 2002, 63 (Suppl): s21-
6.
Tacev T, Ptácková B, Strnad V: Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study. Strahlenther Onkol. 2003, 179: 377-384. 10.1007/s00066-003-1006-3.CrossRefPubMed
7.
Elkind MM: DNA damage and cell killing. Cause and effect?. Cancer. 1985, 56: 2351-2363. 10.1002/1097-0142(19851115)56:10<2351::AID-CNCR2820561002>3.0.CO;2-H.CrossRefPubMed
8.
Thompson LH, Brookman KW, Dillehay LE, Carrano AV, Mazrimas JA, Mooney CL, Minkler JL: A CHO-cell strain having hypersensitivity to mutagens, a defect in DNA strand-break repair, and an extraordinary baseline frequency of sister-chromatid exchange. Mutat Res. 1982, 95: 427-440.CrossRefPubMed
9.
Kelland LR, Edwards SM, Steel GG: Induction and rejoining of DNA double-strand breaks in human cervix carcinoma cell lines of differing radiosensitivity. Radiat Res. 1988, 116: 526-538. 10.2307/3577394.CrossRefPubMed
10.
Schwartz JL, Rotmensch J, Giovanazzi S, Cohen MB, Weichselbaum RR: Faster repair of DNA double-strand breaks in radioresistant human tumor cells. Int J Radiat Oncol Biol Phys. 1988, 15: 907-912.CrossRefPubMed
11.
Russell J, Wheldon TE, Stanton P: A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res. 1995, 55: 4915-4921.PubMed
12.
Dahlberg WK, Azzam EI, Yu Y, Little JB: Response of human tumor cells of varying radiosensitivity and radiocurability to fractionated irradiation. Cancer Res. 1999, 59: 5365-69.PubMed
13.
Pearce AG, Segura TM, Rintala AC, Rintala-Maki ND, Lee H: The generation and characterization of a radiation-resistant model system to study radioresistance in human breast cancer cells. Radiat Res. 2001, 156: 739-750. 10.1667/0033-7587(2001)156[0739:TGACOA]2.0.CO;2.CrossRefPubMed
14.
Wei K, Kodym R, Jin C: Radioresistant cell strain of human fibrosarcoma cells obtained after long-term exposure to x-rays. Radiat Environ Biophys. 1998, 37: 133-137. 10.1007/s004110050106.CrossRefPubMed
15.
Ewing D: Production of radiation-resistant E. coli strains by daily X-irradiation. Int J Radiat Biol. 1997, 71: 253-258. 10.1080/095530097144120.CrossRefPubMed
16.
Wazer DE, Joyce M, Jung L, Band V: Alterations in growth phenotype and radiosensitivity after fractionated irradiation of breast carcinoma cells from a single patient. Int J Radiat Oncol Biol Phys. 1993, 26: 81-88.CrossRefPubMed
17.
Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Haraguchi N, Inoue H, Murayama S, Mori M: Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. Int J Oncol. 2006, 28: 705-713.PubMed
18.
Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y, Yamagishi H: Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer. 2004, 91: 1543-1550. 10.1038/sj.bjc.6602187.CrossRefPubMedPubMedCentral
19.
Chang JT, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, Wang TH, Lee LY, Cheng AJ: Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther. 2007, 6: 2271-2279. 10.1158/1535-7163.MCT-06-0801.CrossRefPubMed
20.
Maity A, Kao GD, Muschel RJ, McKenna WG: Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys. 1997, 37: 639-53.CrossRefPubMed
21.
Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004, 59: 928-942. 10.1016/j.ijrobp.2004.03.005.CrossRefPubMed
22.
Iliakis G, Metzger L, Muschel RJ, McKenna WG: Induction and repair of DNA double strand breaks in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Cancer Res. 1990, 50: 6575-6579.PubMed
23.
Verheij M, Bartelink H: Radiation-induced apoptosis. Cell Tissue Res. 2000, 301: 133-142. 10.1007/s004410000188.CrossRefPubMed
24.
Meyn RE, Stephens LC, Milas L: Programmed cell death and radioresistance. Cancer Metastasis Rev. 1996, 15: 119-131. 10.1007/BF00049491.CrossRefPubMed
25.
Bentzen SM: Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006, 6: 702-713. 10.1038/nrc1950.CrossRefPubMed
26.
Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y: Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia. 2002, 4: 295-303. 10.1038/sj.neo.7900251.CrossRefPubMedPubMedCentral
27.
Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung TH, Lo KW, Yim SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina E, McKinnon RD, Denhardt DT, Chin KV, Chung TK: Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res. 2003, 9: 5486-5492.PubMed
28.
Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, Nakamura Y, Katagiri T: Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004, 60: 237-248.CrossRefPubMed
29.
Chung YM, Kim BG, Park CS, Huh SJ, Kim J, Park JK, Cho SM, Kim BS, Kim JS, Yoo YD, Bae DS: Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer. 2005, 117: 194-201. 10.1002/ijc.21180.CrossRefPubMed
30.
Wong YF, Sahota DS, Cheung TH, Lo KW, Yim SF, Chung TK, Chang AM, Smith DI: Gene expression pattern associated with radiotherapy sensitivity in cervical cancer. Cancer J. 2006, 12: 189-193. 10.1097/00130404-200605000-00006.CrossRefPubMed
31.
Harima Y, Sawada S, Miyazaki Y, Kin K, Ishihara H, Imamura M, Sougawa M, Shikata N, Ohnishi T: Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. Am J Clin Oncol. 2003, 26: e80-85. 10.1097/00000421-200308000-00028.PubMed
32.
Fornace AJ, Amundson SA, Bittner M, Myers TG, Meltzer P, Weinsten JN, Trent J: The complexity of radiation stress responses: analysis by informatics and functional genomics approaches. Gene Expr. 1999, 7: 387-400.PubMed
33.
Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 1994, 31: 1-13. 10.1016/0167-8140(94)90408-1.CrossRefPubMed
34.
Rouault JP, Falette N, Guéhenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A: Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet. 1996, 14: 482-486. 10.1038/ng1296-482.CrossRefPubMed
35.
Wang G, Zhang XR, Hu L, Wang J, Leng ER, Fang DC, Yang XM, Zhang Y, He FC: Rapid induction of mRNAs for liver regeneration genes by hepatopoietin and partial hepatectomy. Zhonghua Gan Zang Bing Za Zhi. 2002, 10: 256-259.PubMed
36.
Guardavaccaro D, Corrente G, Covone F, Micheli L, D'Agnano I, Starace G, Caruso M, Tirone F: Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol. 2000, 20: 1797-1815. 10.1128/MCB.20.5.1797-1815.2000.CrossRefPubMedPubMedCentral
37.
el-Ghissassi F, Valsesia-Wittmann S, Falette N, Duriez C, Walden PD, Puisieux A: BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene. 2002, 21: 6772-6778. 10.1038/sj.onc.1205888.CrossRefPubMed
38.
Klopp AH, Jhingran A, Ramdas L, Story MD, Broadus RR, Lu KH, Eifel PJ, Buchholz TA: Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008, 71: 226-236.CrossRefPubMed
39.
Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, Mazzacurati L, Li X, Petrik KL, Rajasekaran B, Wu M, Zhan Q: GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene. 2002, 21: 8696-8704. 10.1038/sj.onc.1206034.CrossRefPubMed
40.
Takekawa M, Saito H: A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998, 95: 521-530. 10.1016/S0092-8674(00)81619-0.CrossRefPubMed
41.
Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA: Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999, 97: 575-586. 10.1016/S0092-8674(00)80769-2.CrossRefPubMed
Metadata
Title
Microarray analysis of DNA damage repair gene expression profiles in cervical cancer cells radioresistant to 252Cf neutron and X-rays
Authors
Yi Qing
Xue-Qin Yang
Zhao-Yang Zhong
Xin Lei
Jia-Yin Xie
Meng-Xia Li
De-Bing Xiang
Zeng-Peng Li
Zhen-Zhou Yang
Ge Wang
Dong Wang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-71

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Serum vitamin D levels and survival of patients with colorectal cancer: Post-hoc analysis of a prospective cohort study

Study protocol

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)

Research article

Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion

Research article

5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice

Research article

Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates

Research article

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits